UK Markets closed

Compass Therapeutics, Inc. (CMPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0000+0.2500 (+9.09%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 34.4700
52-week low 31.2500
50-day moving average 32.6747
200-day moving average 32.4746

Share statistics

Avg vol (3-month) 3148.07k
Avg vol (10-day) 360.82k
Shares outstanding 598.03M
Implied shares outstanding 6N/A
Float 863.53M
% held by insiders 110.85%
% held by institutions 161.71%
Shares short (14 Jul 2022) 473.49k
Short ratio (14 Jul 2022) 40.36
Short % of float (14 Jul 2022) 40.10%
Short % of shares outstanding (14 Jul 2022) 40.07%
Shares short (prior month 14 Jun 2022) 484.16k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.97%
Return on equity (ttm)-97.55%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.53M
Net income avi to common (ttm)-81.92M
Diluted EPS (ttm)-1.4350
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)136.38M
Total cash per share (mrq)1.35
Total debt (mrq)3.77M
Total debt/equity (mrq)2.80
Current ratio (mrq)15.03
Book value per share (mrq)0.39

Cash flow statement

Operating cash flow (ttm)-22M
Levered free cash flow (ttm)-11.23M